Nervgen Pharma (NGEN) Long-Term Investments (2025 - 2026)
Nervgen Pharma (NGEN) posted quarterly Long-Term Investments of $6.8 million for Q1 2026, down 36.93% quarter-over-quarter from $10.8 million in Q4 2025.
Nervgen Pharma (NGEN) Long-Term Investments (2025 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Long-Term Investments for 2 consecutive years, with $6.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments changed N/A year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (changed N/A YoY), while the FY2025 annual figure was $10.8 million, changed N/A from the prior year.
- Long-Term Investments retreated to $6.8 million in Q1 2026 per NGEN's latest filing, from $10.8 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $10.8 million in Q4 2025 and bottomed at $6.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Nervgen Pharma | 168.94 Mn | 168.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.81 Mn |
| Dec 31, 2025 | 10.80 Mn |